JMJingyi Ma

Jingyi Ma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jingyi Ma has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A drug-repurposing screen of FDA- and EMA-approved drugs identifies two NF-κB inhibitors active against eumycetoma

    by Jingyi Ma, Bjorn R van Doodewaerd, Bernhard Biersack, Annelies Verbon, Paul P Geurink, Wendy W J van de Sande

    Background: Mycetoma caused by Madurella mycetomatis (eumycetoma) is a neglected tropical disease that forms tumorous lesions in the subcutaneous tissue. The current standard treatment for eumycetoma consists of antifungal treatment combined with surgery, with limited success rates. Due to lack of investment, there are currently no large drug discovery programmes for mycetoma. Repurposing screening can therefore offer an effective and economical way to identify drugs that can be effective in eumycetoma treatment. Therefore, in this study we determined the in vitro activity and in vivo efficacy of 5631 compounds present in the Oncode Drug Repurposing library. Methods: In total, 5631 drugs from the Oncode Drug Repurposing library were screened for in vitro activity against M. mycetomatis using a CLSI-based in vitro susceptibility assay and CellTiter-Glo as a viability dye. Compounds that inhibited the metabolic activity were tested for in vivo activity in M. mycetomatis-infected Galleria mellonella larvae. Results: Twenty-eight compounds out of the 5631 drugs were able to inhibit the metabolic activity of M. mycetomatis at 2 µM. Seventeen of the 28 compounds were azoles and 2 were toxic to G. mellonella and therefore not screened further. Two from the remaining 9 compounds, bay117085 (log-rank, P = 0.0494) and IMD-0354 (log-rank, P = 0.0043), prolonged the survival of M. mycetomatis-infected larvae. Both compounds were designed as NF-κB inhibitors. Conclusions: NF-κB inhibitors bay117085 and IMD-0354 were able to prolong the survival of M. mycetomatis-infected larvae.


  • Open Access

    Structure–activity relationships of fenarimol analogues with potent in vitro and in vivo activity against Madurella mycetomatis , the main causative agent of mycetoma

    by Hung Phat Duong, Dmitrij Melechov, Wilson Lim, Jingyi Ma, Kymberley R. Scroggie, Luxsika Rajendra, Benjamin Perry, Luiza R. Cruz, Rahman Shah Zaib Saleem, Peter J. Rutledge, et al.

    From 185 fenarimol analogues evaluated against M. mycetomatis , 22 were found to be potent in vitro , with 5 showing promise in an in vivo model; low predicted log D (in vivo efficacy, providing insights for future design.


  • Open Access

    Structure–activity relationships of fenarimol analogues with potent in vitro and in vivo activity against Madurella mycetomatis, the main causative agent of eumycetoma

    by Hung Phat Duong, Dmitrij Melechov, Wilson Lim, Jingyi Ma, Kymberley Scroggie, Luxsika Rajendra, Ben Perry, Luiza Cruz, Peter Rutledge, Alice Motion, et al.

    The fenarimol analogue EPL-BS1246 was previously discovered to be potent against Madurella mycetomatis, the causative agent of the neglected tropical disease eumycetoma. Further evaluation of a small set of fenarimol analogues in vivo revealed a correlation between efficacy and the lipophilicity (logD) of the analogues. To explore both this correlation and the series structure-activity relationship (SAR), we have evaluated a total of 185 fenarimol analogues derived from five different daughter chemotypes. Potent (MIC50 <9 μM) in vitro activity was found for 22 analogues, five of which gave promising results in an in vivo larval survival assay. Again, a trend towards prolonged larval survival (better in vivo activity) was noted in analogues with logD values <2.5. Insights into the SAR could be gleaned that suggested optimal substituents for the rings forming the fenarimol core.

  • Open Access

    Ibrexafungerp prolongs survival and reduces the eumycetoma grain size in Galleria mellonella infection models of two different causative agents of eumycetoma

    by Jingyi Ma, Kimberly Eadie, Mickey Konings, Ahmed Fahal, Annelies Verbon, Wendy W J van de Sande

    Objectives: Eumycetoma is a neglected tropical fungal disease of the subcutaneous tissue that is currently not treatable with medication only. Standard itraconazole therapy is combined with surgical excision of the lesion. Recently, ibrexafungerp, a novel oral antifungal agent inhibiting 1,3-β-D-glucan synthesis, was approved by the United States Food and Drug Administration (FDA) for the treatment of vulvovaginal candidiasis. In this study we determined the in vitro activity and in vivo efficacy of ibrexafungerp in eumycetoma causative agents. Methods: In vitro activity of ibrexafungerp and itraconazole was determined against 30 Madurella and 7 Falciformispora isolates by standardized in vitro susceptibility assays. The in vivo efficacy of ibrexafungerp, itraconazole and the combination of ibrexafungerp and itraconazole was determined by measuring the 10 day survival in M. mycetomatis and F. senegalensis grain models in Galleria mellonella larvae. Grain number and size were determined in Grocott- and haematoxylin and eosin–stained sections. Results: Ibrexafungerp inhibited the growth of Madurella and Falciformispora species with MICs ranging from 4 to 64 mg/L and from 8 to 32 mg/L, respectively. In G. mellonella larvae, ibrexafungerp was not toxic and prolonged the survival in M. mycetomatis-infected larvae 10 days after infection, but not in F. senegalensis-infected larvae. Combining ibrexafungerp with itraconazole prolonged the survival of M. mycetomatis- and F. senegalensis-infected larvae. Treatment with ibrexafungerp alone and in combination resulted in smaller grains in M. mycetomatis-infected larvae. Conclusions: Ibrexafungerp showed in vitro activity and in vivo efficacy against the two most common eumycetoma causative agents.


  • Open Access

    The performance and costs of XTT, resazurin, MTS and luciferin as viability dyes in in vitro susceptibility testing of Madurella mycetomatis

    by Jingyi Ma, Kimberly Eadie, Ahmed Fahal, Annelies Verbon, Wendy W J van de Sande

    in vitro susceptibility testing for the non-sporulating fungus Madurella mycetomatis is performed with a hyphal suspension as starting inoculum and a viability dye for endpoint reading. Here we compared the performance of four different viability dyes for their use in in vitro susceptibility testing of M. mycetomatis. To compare the reproducibility and the agreement between the viability dyes 2,3-bis-(2-methoxy-4-nitro-5-sulfphenyl)-2H-tetrazolium-5-carboxanilide salt (XTT), resazurin, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTS) and luciferin, the in vitro susceptibilities of 14 genetically diverse M. mycetomatis isolates were determined for itraconazole and amphotericin B. The reproducibility, agreement, price and ease of use were compared. Each of the four dyes gave highly reproducible results with >85.7% reproducibility. Percentage agreement ranged between 78.9% and 92.9%. Resazurin was the most economical to use (0.0009 €/minimal inhibitory concentration [MIC]) and could be followed in real time. Luciferin omitted the need to transfer the supernatant to a new 96-well plate, but cost 6.07 €/MIC. All four viability dyes were suitable to determine the in vitro susceptibility of M. mycetomatis against itraconazole and amphotericin B. Based on the high reproducibility, high percentage agreement, price and possibility to monitor in real time, resazurin was the most suited for routine in vitro susceptibility testing in the diagnostic laboratory in mycetoma-endemic countries. Because luminescence could be measured directly without the need to transfer the supernatant to a new 96-well plate, luciferin is suitable for drug-screening campaigns. To determine the in vitro susceptibility testing in the non-sporulating fungus Madurella mycetomatis, a viability dye is needed for endpoint reading. In this study we tested the viability dyes XTT, resazurin, MTS and luciferin for their use in in vitro susceptibility testing. It appeared that they all could be used but there were differences in time to result and costs associated with them.


  • Open Access

    A Falciformispora senegalensis grain model in Galleria mellonella larvae

    by Jingyi Ma, Mickey Konings, Annelies Verbon, Wendy W J van de Sande

    Eumycetoma is a subcutaneous implantation mycosis often found in the foot. One of the hallmarks of eumycetoma is the formation of grains. These grains are either black or white, and the consistency and morphology differs per causative agent. The two most common causative agents of black-grain eumycetoma are Madurella mycetomatis and Falciformispora senegalensis. Since grains cannot be formed in vitro, in vivo models are needed to study grain formation. Here, we used the invertebrate Galleria mellonella to establish an in vivo grain model for F. senegalensis. Three different F. senegalensis strains were selected, and four different inocula were used to infect G. mellonella larvae, ranging from 0.04 mg/larvae to 10 mg/larvae. Larval survival was monitored for 10 days. Grain formation was studied macroscopically and histologically. The efficacy of antifungal therapy was determined for itraconazole, amphotericin B, and terbinafine. A concentration of 10 mg F. senegalensis per larva was lethal for the majority of the larvae within 10 days. At this inoculum, grains were formed within 24 h after infection. The grains produced in the larvae resembled those formed in human patients. Amphotericin B given at 1 mg/kg 4 h, 28 h, and 52 h after infection prolonged larval survival. No enhanced survival was noted for itraconazole or terbinafine. In conclusion, we developed a F. senegalensis grain model in G. mellonella larvae in which grains were formed that were similar to those formed in patients. This model can be used to monitor grain formation over time and study antifungal efficacy. Within eumycetoma lesions, the causative agents are embedded in grains. However, the grains differ per causative agent. In this study, we developed a grain model of Falciformispora senegalensis in the larvae of Galleria mellonella. This model can be used in the future to study the efficacy of novel antifungal agents.


  • Open Access

    Antifungal Activity of Natural Naphthoquinones and Anthraquinones against Madurella mycetomatis

    by Jingyi Ma, Matthew Todd, Wendy W. J. van de Sande, Bernhard Biersack

    Eumycetoma, the fungal form of the neglected tropical disease mycetoma, is a crippling infectious disease with low response rates to currently available antifungal drugs. In this study, a series of natural naphthoquinones and anthraquinones was evaluated for their activity against Madurella mycetomatis, which is the most common causative agent of eumycetoma. The metabolic activity of Madurella mycetomatis as well as the viability of Galleria mellonella larvae upon treatment with quinones was investigated. Several hydroxy‐substituted naphthoquinones exhibited activity against Madurella mycetomatis. In particular, naphthazarin (5,8‐dihydroxy‐1,4‐naphthoquinone) was identified as a considerably active antifungal compound against Madurella mycetomatis (IC50=1.4 μM), while it showed reduced toxicity to Galleria mellonella larvae, which is a well‐established in vivo invertebrate model for mycetoma drug studies.